Our Services
Medical Information
Helpful Resources
Published on: 3/12/2026
MAOIs are a medically proven next step for treatment resistant depression when at least two adequate antidepressant trials have failed, often helping most with atypical features, severe fatigue, or coexisting anxiety by increasing serotonin, norepinephrine, and dopamine.
There are several factors to consider, including dietary tyramine precautions, medication interactions and washout, monitoring needs, side effects, and options like the selegiline patch; see the complete details below to guide safe, effective next steps with your clinician.
If you've tried multiple antidepressants and still feel stuck, you are not alone. Treatment‑resistant depression (TRD) is more common than many people realize. In general, TRD is defined as major depressive disorder that does not improve after trying at least two different antidepressants at adequate doses and duration.
When standard treatments fail, many patients and even some clinicians hesitate to consider older medications. One of the most overlooked but medically proven options is MAOIs for TRD.
Monoamine oxidase inhibitors (MAOIs) have been around for decades. While they require careful management, they remain one of the most effective treatments for certain forms of hard‑to‑treat depression.
Let's break down what this means for you in clear, practical terms.
Treatment‑resistant depression doesn't mean your depression is untreatable. It means the first-line medications didn't work well enough.
Common first-line antidepressants include:
If you've tried two or more of these — at proper doses, for at least 6–8 weeks each — and still have significant symptoms, your depression may be considered treatment resistant.
Symptoms often include:
If these symptoms sound familiar and you want to better understand where you stand, Ubie offers a free AI-powered Depression symptom checker that takes just minutes to complete and can help you prepare for a more informed conversation with your doctor.
MAOIs (monoamine oxidase inhibitors) are a class of antidepressants that work differently from most modern medications.
They block an enzyme called monoamine oxidase. This enzyme breaks down key brain chemicals that regulate mood, including:
By blocking this enzyme, MAOIs increase the availability of these mood-regulating neurotransmitters.
Examples of MAOIs include:
Clinical research and decades of psychiatric experience show that MAOIs for TRD can be highly effective, especially in people who:
In fact, studies suggest MAOIs may outperform other antidepressants in certain subtypes of treatment-resistant depression.
Most modern antidepressants primarily affect serotonin (and sometimes norepinephrine). MAOIs increase serotonin, norepinephrine, and dopamine simultaneously.
For some patients, especially those with low motivation, severe fatigue, or emotional numbness, this broader mechanism can make a meaningful difference.
While newer medications often receive more attention, MAOIs have decades of real-world clinical data supporting their effectiveness. They are not experimental. They are established, evidence-based treatments — just underutilized.
There are two main reasons:
MAOIs require avoiding high-tyramine foods. Tyramine can interact with MAOIs and cause a dangerous rise in blood pressure.
Foods typically restricted include:
However, modern dietary guidelines for MAOIs are more flexible than in the past. Many foods once restricted are now considered safe in moderate amounts. A knowledgeable psychiatrist can provide a clear and manageable food list.
MAOIs cannot be combined with many other medications, including:
Switching to an MAOI requires a careful medication washout period under medical supervision.
These precautions are serious — but manageable with proper medical guidance.
When prescribed and monitored appropriately, MAOIs can be safe and effective.
That said, they require:
They are not casual medications. But for many people with TRD, the potential benefits outweigh the inconvenience.
Importantly, transdermal selegiline (a skin patch) may carry fewer dietary restrictions at lower doses, which can make it an appealing option for some patients.
You might consider discussing MAOIs for TRD with a psychiatrist if:
MAOIs are often particularly effective in people who feel "shut down" rather than agitated.
Starting an MAOI typically involves:
Improvements may begin within 2–4 weeks, but full effects can take longer.
Like all antidepressants, MAOIs can cause side effects. These may include:
Your doctor will monitor these closely.
Depression can become life-threatening if it leads to suicidal thoughts or behaviors.
If you are experiencing:
You should seek immediate medical care or emergency assistance.
For anything potentially life‑threatening or serious, speak to a doctor right away.
It's important not to "sugar coat" things: MAOIs require responsibility. They are not as simple as taking an SSRI and forgetting about it.
But it's equally important not to dismiss them.
For many people with TRD, MAOIs represent:
They are not outdated. They are underused.
If you've been struggling despite multiple treatments, don't assume you're out of options.
Consider:
Most importantly, speak openly with a qualified medical professional. Treatment-resistant depression requires personalized, expert care.
You deserve a treatment plan that is thoughtful, evidence-based, and tailored to you.
MAOIs may not be right for everyone. But for the right patient — under the right supervision — they can be life-changing.
If you are struggling, do not give up. There are still medically proven options available. And one of them may be closer than you think.
(References)
* Fiedorowicz JG, Coryell WH. Monoamine oxidase inhibitors in the treatment of resistant depression: current perspectives. J Affect Disord. 2018 Apr 15;231:166-172. doi: 10.1016/j.jad.2017.12.083. Epub 2018 Jan 9. PMID: 29329068.
* Shulman KI, Herrmann N, Walker SE. MAOIs in the Age of Modern Antidepressants: Past, Present, and Future. CNS Drugs. 2013 Oct;27(10):859-69. doi: 10.1007/s40263-013-0097-4. PMID: 23740608.
* Amsterdam JD, Shults J, Kan RY. Phenelzine for Treatment-Resistant Depression: A Retrospective Analysis. J Clin Psychopharmacol. 2019 Jun;39(3):214-219. doi: 10.1097/JCP.0000000000001035. PMID: 30896426.
* Cipriani A, Furukawa TA, Salanti G, Chaimani A, Thornton T, Takeshima N, Watanabe N, Ogawa Y, Yajima T, Egawa M, Sawatari C, Nakajima S, Yoshio K, Kishi T, Yagi G, Imai H. Tranylcypromine for treatment-resistant depression: A systematic review and meta-analysis. J Affect Disord. 2021 Jul 15;290:314-322. doi: 10.1016/j.jad.2021.04.047. Epub 2021 Apr 17. PMID: 33827608.
* Locher C, Bschor T, Schroeck H, Holsboer F, Stier B, Schneider-Axmann T, Kellner M. Monoamine Oxidase Inhibitors (MAOIs) for Treatment-Resistant Depression: A Critical Review. Pharmacopsychiatry. 2021 Nov;54(6):299-310. doi: 10.1055/a-1563-0095. Epub 2021 Oct 6. PMID: 34614661.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.